Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

FDA panel for Vascepa means likely delay
Amarin Corp. plc (NASDAQ:AMRN) said it expects FDA to extend the PDUFA date for Vascepa icosapent ethyl to late December from Sept. 28 after the agency scheduled an advisory committee meeting, tentatively set for Nov. 14, to discuss the candidate's sNDA to reduce cardiovascular risk. Amarin, which announced the news after market close, fell $4.11 (23%) to $13.70 in after-hours trading.

Alexandria nabs more Seattle land
Alexandria Real Estate Equities Inc. will purchase 2.9 acres of property near its life sciences and biotech office and lab spaces in the South Lake Union area of Seattle for $143.5 million to provide housing, a community center and transportation. Alexandria is using its life sciences real estate revenue to build its portfolio of biotech investments (see "Alexandria Parlays Growing Life Sciences Real Estate Holdings into a Flurry of VC Deals")...